{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.46","value":"-9.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Quality of Life (QoL) as measured by the European Quality of Life 5-dimensional questionnaire (EQ-5D) for Cohorts A. Visual Analogue Scale scores assessed based on drawn scale from 0(worst imaginable state) to 100(best imaginable state). Subjects chose their health state on scale based on their situation by themselves. A negative outcome indicates a decrease in score compared to the baseline value.","dispersionType":"Standard Deviation","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"MEAN","populationDescription":"The full analysis set (FAS) followed the intent to treat (ITT) principle and consisted of all subjects who received at least one dose of AFM13.","reportingStatus":"POSTED","timeFrame":"From baseline until final study visit, up to 199 weeks.","title":"European Quality of Life 5-dimensional Visual Analogue Scale Scores (EQ-5D)","type":"SECONDARY","unitOfMeasure":"score on a scale"}